M

MacroGenics
D

MGNX

3.21000
USD
0.02
(0.63%)
مفتوح الان
حجم التداول
4,094
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
201,784,485
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARRY
    0.31000
    (5.52%)
    5.93000 USD
    B
    BLUE
    -0.81000
    (-9.54%)
    7.68000 USD
    C
    CRSP
    -0.510
    (-1.25%)
    40.210 USD
    E
    EDIT
    -0.05500
    (-4.17%)
    1.26500 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    N
    NKTR
    -0.01920
    (-2.09%)
    0.90080 USD
    S
    SGMO
    -0.04000
    (-1.61%)
    2.45000 USD
    X
    XNCR
    0.100
    (0.41%)
    24.260 USD
    المزيد
الأخبار
المقالات

العنوان: MacroGenics

القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).